These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38973363)

  • 21. [Gastrointestinal stromal tumors (GIST)].
    Jaros D; Bozic B; Sebesta C
    Wien Med Wochenschr; 2023 Jun; 173(9-10):201-205. PubMed ID: 36155864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ripretinib (Qinlock) for GIST.
    Med Lett Drugs Ther; 2021 Apr; 63(1621):e56-e57. PubMed ID: 33830971
    [No Abstract]   [Full Text] [Related]  

  • 23. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial.
    Symcox M; Jones RL
    Future Oncol; 2023 Nov; 19(36):2383-2393. PubMed ID: 37594164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
    Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
    Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastrointestinal stromal tumours.
    Blay JY; Kang YK; Nishida T; von Mehren M
    Nat Rev Dis Primers; 2021 Mar; 7(1):22. PubMed ID: 33737510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New insights into the clinical management of advanced gastrointestinal stromal tumors.
    Italiano A
    Expert Opin Pharmacother; 2021 Mar; 22(4):439-447. PubMed ID: 33307872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous
    Bauer S; Heinrich MC; George S; Zalcberg JR; Serrano C; Gelderblom H; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Meade J; Su Y; Ruiz-Soto R; Blay JY; von Mehren M; Schöffski P
    Clin Cancer Res; 2021 Dec; 27(23):6333-6342. PubMed ID: 34503977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
    Serrano C; Mariño-Enríquez A; Tao DL; Ketzer J; Eilers G; Zhu M; Yu C; Mannan AM; Rubin BP; Demetri GD; Raut CP; Presnell A; McKinley A; Heinrich MC; Czaplinski JT; Sicinska E; Bauer S; George S; Fletcher JA
    Br J Cancer; 2019 Mar; 120(6):612-620. PubMed ID: 30792533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The management of metastatic GIST: current standard and investigational therapeutics.
    Kelly CM; Gutierrez Sainz L; Chi P
    J Hematol Oncol; 2021 Jan; 14(1):2. PubMed ID: 33402214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.
    Lee DM; Sun A; Patil SS; Liu L; Rao AV; Trent PT; Ali AA; Liu C; Rausch JL; Presutti LD; Kaczorowski A; Schneider F; Amankulor NM; Shuda M; Duensing A
    Sci Rep; 2022 May; 12(1):8275. PubMed ID: 35585158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.
    Banks E; Grondine M; Bhavsar D; Barry E; Kettle JG; Reddy VP; Brown C; Wang H; Mettetal JT; Collins T; Adeyemi O; Overman R; Lawson D; Harmer AR; Reimer C; Drew L; Packer MJ; Cosulich S; Jones RD; Shao W; Wilson D; Guichard S; Fawell S; Anjum R
    Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32350132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.
    Franck C; Rosania R; Franke S; Haybaeck J; Canbay A; Venerito M
    Digestion; 2019; 99(2):179-184. PubMed ID: 30179868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors.
    Boichuk S; Dunaev P; Galembikova A; Mustafin I; Valeeva E
    Anticancer Drugs; 2018 Jul; 29(6):549-559. PubMed ID: 29697413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours.
    Naito Y; Nishida T; Doi T
    Gastric Cancer; 2023 May; 26(3):339-351. PubMed ID: 36913072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
    Bauer S; Jones RL; Blay JY; Gelderblom H; George S; Schöffski P; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Su Y; Meade J; Wang T; Sherman ML; Ruiz-Soto R; Heinrich MC
    J Clin Oncol; 2022 Dec; 40(34):3918-3928. PubMed ID: 35947817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of PI3K and MAPK pathways along with KIT inhibitors as a strategy to overcome drug resistance in gastrointestinal stromal tumors.
    Gupta A; Ma S; Che K; Pobbati AV; Rubin BP
    PLoS One; 2021; 16(7):e0252689. PubMed ID: 34324512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.
    Serrano C; Bauer S
    Curr Oncol Rep; 2022 Feb; 24(2):151-159. PubMed ID: 35061196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TRIM21/USP15 balances ACSL4 stability and the imatinib resistance of gastrointestinal stromal tumors.
    Cui Z; Sun H; Gao Z; Li C; Xiao T; Bian Y; Liu Z; Gu T; Zhang J; Li T; Zhou Q; He Z; Li B; Li F; Xu Z; Xu H
    Br J Cancer; 2024 Mar; 130(4):526-541. PubMed ID: 38182686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ripretinib for the treatment of advanced, imatinib-resistant gastrointestinal stromal tumors.
    Liu WZ; Du YQ; Shen Q; Tao KX; Zhang P
    J Dig Dis; 2023 Sep; ():. PubMed ID: 37706279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.